BioWorld Asia

March 17, 2010

View Archived Issues

Ablynx Growing Post-IPO, Adds $68M to Advance Nanobodies

A Glimpse of the Microbial Genomes Inside our Guts

€13M Restocks Antisense Coffers for Cancer Drug Trial

No Abstract Read More

Kuros Achieves First Proof in Repairing Bone Fractures

Immunotherapy Still an 'Option,' Transgene-Novartis Deal Proves

Rhythm Hits Stride, Raises $21M in Series A for Phase I Peptides

Other News To Note

Sans Partner, Oxford BioMedica Restarting TroVax Development

LONDON - Oxford BioMedica plc is restarting clinical development of its TroVax cancer immunotherapy 12 months after the failure of a Phase III trial in renal cancer led partner Sanofi-Aventis SA to drop the product. (BioWorld International) Read More

Today's news in brief

BioWorld

BioWorld briefs for June 25, 2026.

Have brain-computer interfaces finally arrived?

BioWorld

More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...